27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie.
Looking at options history for AbbVie (NYSE:ABBV) we detected 25 trades.
If we consider the specifics of each trade, it is accurate to state that 32% of the investors opened trades with bullish expectations and 68% with bearish.
From the overall spotted trades, 11 are puts, for a total amount of $593,316 and 14, calls, for a total amount of $795,585.
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $125.0 to $195.0 for AbbVie over the last 3 months.
Volume & Open Interest Development
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in AbbVie's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to AbbVie's substantial trades, within a strike price spectrum from $125.0 to $195.0 over the preceding 30 days.
AbbVie Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | CALL | TRADE | BEARISH | 01/17/25 | $5.0 | $4.8 | $4.8 | $195.00 | $163.2K | 1.2K | 341 |
| ABBV | PUT | TRADE | BULLISH | 01/17/25 | $21.35 | $21.0 | $21.0 | $185.00 | $128.1K | 32 | 67 |
| ABBV | CALL | SWEEP | BEARISH | 04/26/24 | $2.28 | $2.12 | $2.28 | $175.00 | $91.2K | 279 | 2.2K |
| ABBV | CALL | TRADE | BEARISH | 05/17/24 | $5.4 | $5.3 | $5.3 | $170.00 | $90.1K | 5.6K | 292 |
| ABBV | PUT | TRADE | BEARISH | 01/17/25 | $2.5 | $2.28 | $2.5 | $130.00 | $85.0K | 1.7K | 340 |
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
In light of the recent options history for AbbVie, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Where Is AbbVie Standing Right Now?
- Currently trading with a volume of 6,634,397, the ABBV's price is up by 1.25%, now at $170.0.
- RSI readings suggest the stock is currently may be approaching oversold.
- Anticipated earnings release is in 21 days.
What Analysts Are Saying About AbbVie
In the last month, 2 experts released ratings on this stock with an average target price of $192.5.
- An analyst from Barclays persists with their Overweight rating on AbbVie, maintaining a target price of $195.
- An analyst from Guggenheim has decided to maintain their Buy rating on AbbVie, which currently sits at a price target of $190.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, Benzinga Pro gives you real-time options trades alerts.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!